Search by Drug Name or NDC
NDC 00069-2025-25 Comirnaty 0.225 mg/2.25mL Details
Comirnaty 0.225 mg/2.25mL
Comirnaty is a INTRAMUSCULAR INJECTION, SUSPENSION in the VACCINE category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is TOZINAMERAN.
MedlinePlus Drug Summary
What is COVID-19? COVID-19 disease is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been seen before. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory (lung) illness, but it can also affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever, chills, cough, shortness of breath, fatigue, muscle or body aches, headache, loss of taste or smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhea.
Related Packages: 00069-2025-25Last Updated: 11/30/2022
MedLinePlus Full Drug Details: COVID-19 Vaccine, mRNA (Moderna)
What is COVID-19? COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory (lung) illness, but it can also affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness leading to death. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever, chills, cough, shortness of breath, fatigue, muscle or body aches, headache, loss of taste or smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhea.
Related Packages: 00069-2025-25Last Updated: 11/30/2022
MedLinePlus Full Drug Details: COVID-19 Vaccine, mRNA (Pfizer-BioNTech)
Product Information
| NDC | 00069-2025 |
|---|---|
| Product ID | 0069-2025_a0e017dc-e076-48f3-9cb6-c2d3608b26f8 |
| Associated GPIs | 17100002401824 |
| GCN Sequence Number | 082671 |
| GCN Sequence Number Description | COVID-19 vac, tris(Pfizer)/PF VIAL 30 MCG/0.3 INTRAMUSC |
| HIC3 | Z0L |
| HIC3 Description | COVID-19 VACCINES |
| GCN | 50979 |
| HICL Sequence Number | 047574 |
| HICL Sequence Number Description | COVID-19 VAC MRNA,TRIS(PFIZER)/PF |
| Brand/Generic | Brand |
| Proprietary Name | Comirnaty |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | COVID-19 Vaccine, mRNA |
| Product Type | VACCINE |
| Dosage Form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR |
| Active Ingredient Strength | 0.225 |
| Active Ingredient Units | mg/2.25mL |
| Substance Name | TOZINAMERAN |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA125742 |
| Listing Certified Through | n/a |
Package
NDC 00069-2025-25 (00069202525)
| NDC Package Code | 0069-2025-25 |
|---|---|
| Billing NDC | 00069202525 |
| Package | 25 VIAL, GLASS in 1 CARTON (0069-2025-25) / 2.25 mL in 1 VIAL, GLASS (0069-2025-01) |
| Marketing Start Date | 2022-05-18 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |